Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)

Ali Taher, Vip Viprakasit, Maria Domenica Cappellini, Pranee Sutcharitchan, Richard Ward, Dalia Mahmoud, Abderrahmane Laadem, Anzalee Khan, Chad Gwaltney, Gale Harding, Kenneth Attie, Xiaosha Zhang, Jun Zou, Joseph Pariseau, X. Henry Hu, Antonis Kattamis

Research output: Contribution to journalArticle

Abstract

β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.

Original languageEnglish
Pages (from-to)171-176
JournalAmerican Journal of Hematology
Volume94
Issue number2
DOIs
Publication statusPublished - 2019

Fingerprint

Thalassemia
Lebanon
Greece
Interviews
United States Food and Drug Administration
Patient Reported Outcome Measures
Anemia
Quality of Life
Aptitude
Globins
Erythropoiesis
Health
Dyspnea
Canada
Headache
Hemoglobins

ASJC Scopus subject areas

  • Hematology

Cite this

Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©). / Taher, Ali; Viprakasit, Vip; Cappellini, Maria Domenica; Sutcharitchan, Pranee; Ward, Richard; Mahmoud, Dalia; Laadem, Abderrahmane; Khan, Anzalee; Gwaltney, Chad; Harding, Gale; Attie, Kenneth; Zhang, Xiaosha; Zou, Jun; Pariseau, Joseph; Hu, X. Henry; Kattamis, Antonis.

In: American Journal of Hematology, Vol. 94, No. 2, 2019, p. 171-176.

Research output: Contribution to journalArticle

Taher, A, Viprakasit, V, Cappellini, MD, Sutcharitchan, P, Ward, R, Mahmoud, D, Laadem, A, Khan, A, Gwaltney, C, Harding, G, Attie, K, Zhang, X, Zou, J, Pariseau, J, Hu, XH & Kattamis, A 2019, 'Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)', American Journal of Hematology, vol. 94, no. 2, pp. 171-176. https://doi.org/10.1002/ajh.25343
Taher, Ali ; Viprakasit, Vip ; Cappellini, Maria Domenica ; Sutcharitchan, Pranee ; Ward, Richard ; Mahmoud, Dalia ; Laadem, Abderrahmane ; Khan, Anzalee ; Gwaltney, Chad ; Harding, Gale ; Attie, Kenneth ; Zhang, Xiaosha ; Zou, Jun ; Pariseau, Joseph ; Hu, X. Henry ; Kattamis, Antonis. / Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©). In: American Journal of Hematology. 2019 ; Vol. 94, No. 2. pp. 171-176.
@article{cb50d881e0da414f968dd5997d020ebe,
title = "Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO{\circledC})",
abstract = "β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO{\circledC} tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60{\%} were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.",
author = "Ali Taher and Vip Viprakasit and Cappellini, {Maria Domenica} and Pranee Sutcharitchan and Richard Ward and Dalia Mahmoud and Abderrahmane Laadem and Anzalee Khan and Chad Gwaltney and Gale Harding and Kenneth Attie and Xiaosha Zhang and Jun Zou and Joseph Pariseau and Hu, {X. Henry} and Antonis Kattamis",
year = "2019",
doi = "10.1002/ajh.25343",
language = "English",
volume = "94",
pages = "171--176",
journal = "American Journal of Hematology",
issn = "0361-8609",
publisher = "Wiley-Liss Inc.",
number = "2",

}

TY - JOUR

T1 - Development of a patient-reported outcomes symptom measure for patients with nontransfusion-dependent thalassemia (NTDT-PRO©)

AU - Taher, Ali

AU - Viprakasit, Vip

AU - Cappellini, Maria Domenica

AU - Sutcharitchan, Pranee

AU - Ward, Richard

AU - Mahmoud, Dalia

AU - Laadem, Abderrahmane

AU - Khan, Anzalee

AU - Gwaltney, Chad

AU - Harding, Gale

AU - Attie, Kenneth

AU - Zhang, Xiaosha

AU - Zou, Jun

AU - Pariseau, Joseph

AU - Hu, X. Henry

AU - Kattamis, Antonis

PY - 2019

Y1 - 2019

N2 - β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.

AB - β-Thalassemia, a hereditary blood disorder caused by reduced or absent synthesis of the β-globin chain of hemoglobin, is characterized by ineffective erythropoiesis, and can manifest as nontransfusion-dependent thalassemia (NTDT) or transfusion-dependent thalassemia (TDT). Many patients with NTDT develop a wide range of serious complications that affect survival and quality of life (QoL). Patient-reported outcomes (PRO), including health-related QoL (HRQoL), are important tools for determining patient health impairment and selecting appropriate treatment. However, there are currently no disease-specific PRO tools available to assess symptoms related to chronic anemia experienced by patients with NTDT. This study aimed to develop a new, US Food and Drug Administration (FDA)-compliant PRO of chronic anemia symptoms, the NTDT-PRO© tool, for use in patients with NTDT. Participants had a median age of 36 years (range, 18-47) and 60% were female. The initial development of the NTDT-PRO tool involved concept-elicitation interviews with 25 patients from 3 centers (in Lebanon, Greece, and Canada); subsequent interview discussions and clinical input resulted in the generation of 9 items for inclusion in the draft NTDT-PRO. Following a round of cognitive interviews involving 21 patients from 2 centers (in Lebanon and Greece), 4 items (Pain, Headaches, Ability to Concentrate, and Paleness) were removed from the draft NTDT-PRO. The final NTDT-PRO comprises 6 items that measure Tiredness, Weakness, and Shortness of Breath, with or without Physical Activity. The NTDT-PRO is a new disease-specific HRQoL tool for patients with NTDT, developed using a thorough methodology based on FDA 2009 PRO development guidelines.

UR - http://www.scopus.com/inward/record.url?scp=85057310610&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85057310610&partnerID=8YFLogxK

U2 - 10.1002/ajh.25343

DO - 10.1002/ajh.25343

M3 - Article

AN - SCOPUS:85057310610

VL - 94

SP - 171

EP - 176

JO - American Journal of Hematology

JF - American Journal of Hematology

SN - 0361-8609

IS - 2

ER -